2005
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. Journal Of Clinical Oncology 2005, 23: 3243-56. PMID: 15886312, DOI: 10.1200/jco.2005.18.853.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorAntiangiogenic agentsLung cancerSurrogate markerProangiogenic vascular endothelial growth factorMajority of patientsReliable surrogate markerTumor vascular developmentDownstream receptor signalingKey therapeutic strategyEndothelial growth factorVEGF receptor bindingMetastatic diseaseMost patientsCancer deathConventional chemotherapyCommon causeTherapeutic strategiesTherapeutic implicationsTumor typesTumor vasculatureTarget inhibitionAnticancer effectsCytostatic effectReceptor signaling
2003
Targeting the epidermal growth factor receptor: prognostic and clinical implications
Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. European Journal Of Cancer Supplements 2003, 1: 9-15. DOI: 10.1016/s1359-6349(03)80015-0.Peer-Reviewed Original ResearchEpidermal growth factor receptorGrowth factor receptorEGFR tyrosine kinase inhibitor gefitinibFactor receptorTyrosine kinase inhibitor gefitinibCell lung cancerKinase inhibitor gefitinibPerformance statusClinical responseSkin toxicityPrognostic valueDisease characteristicsLung cancerSurrogate markerClinical trialsNovel anticancer agentsInhibitor gefitinibClinical implicationsGefitinibAntitumour activityBiological markersPromising targetExpression levelsTumorigenic processAnticancer agentsSurrogate markers in antiangiogenesis clinical trials
Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. British Journal Of Cancer 2003, 89: 8-14. PMID: 12838293, PMCID: PMC2394225, DOI: 10.1038/sj.bjc.6601035.Peer-Reviewed Original Research